Eli Lilly Sues Six Firms Over Illicit Sales Of Experimental Retatrutide
On Wednesday, August 12, 2026, Eli Lilly sued six companies in U.S. courts, alleging they illegally sold experimental obesity drug retatrutide that is not FDA-approved.[1]
The suits name peptide vendors Astra Peptides, Legendary Peptides, Texas Peptides and Lone Star Peptide, med spa Aesthetic Envy and Striker Pharmacy as defendants.[1] Eli Lilly says the companies marketed and sold research-grade retatrutide to U.S. buyers even though the drug remains in late-stage trials and is not approved by the FDA.[1] Max Denning, an Eli Lilly executive, called the illicit market a global problem and said the company's legal action is only a start.[1]
Retatrutide remains in late-stage clinical trials for obesity and type 2 diabetes and has not been approved by the U.S. Food and Drug Administration.[1] CBS previously documented research-grade retatrutide being advertised and sold in U.S. convenience stores and bodegas as recently as August 8, 2026.[1]
Show source details & analysis (1 source)
📌 Key Facts
- On Wednesday, August 12, 2026, Eli Lilly announced lawsuits against six companies over alleged illicit sales of experimental drug retatrutide.
- Defendants include peptide vendors Astra Peptides, Legendary Peptides, Texas Peptides and Lone Star Peptide, med spa Aesthetic Envy, and Striker Pharmacy.
- Retatrutide is still in late-stage clinical trials for obesity and type 2 diabetes and has not been approved by the FDA.
- Eli Lilly executive Max Denning said the illicit market is a global problem and that the company’s legal action is only a start.
- CBS previously documented research-grade retatrutide being advertised and sold in U.S. convenience stores and bodegas as recently as August 8, 2026.
📰 Source Timeline (1)
Follow how coverage of this story developed over time